Overview:

CRISPR-Cas systems constitute the adaptive immune system in bacteria via RNA-guided endonucleases (1,2). This system has been leveraged to create an exemplary genome editing tool with applications in both basic research and therapeutics development (3). PsmCas13b is a CRISPR-Cas effector that belongs to the class 2 subtype VI-B (3). It processes its own CRISPR array with short andlong direct repeats, cleaves target RNA, and exhibitscollateral RNase activity (3). It has been shown toeffectively target and silence distinct mammalian ssRNAviruses (4).

Accession Number:

WP_013997271

Formulation:

Recombinant protein stored in 50mM Tris, pH7.5, 600mM NaCl, 0.1mM TCEP, and 50% glycerol.

References:

1.Horvath, P., et al. 2010. CRISPR/Cas, the immune system ofbacteria and archaea. Science, 327(5962):167-170.

2.Morange, M. 2015. What history tells us XXXVII. CRISPR-Cas:The disconvery of an immune system in prokaryotes. J. Biosci.40(2):221-223.

3.Smargon, A. A., et al. 2017. Cas13b is a Type VI-B CRISPR-associated RNA-Guided RNAse differentially regulated byaccessory proteins Csx27 and Csx28. Mol. Cell. 65(4):618-630.

4.Freije, C. A., et al. 2019. Programmable Inhibition and